Bench-to-Bedside Development of IMNN-001: A Non-Viral IL-12 Gene Therapy for Advanced Ovarian Cancer.

Anwer K, Sood S, Sparks J, Faller DV, Limon A, Lindborg SR

Open source

DOI
10.3390/pharmaceutics18101250
Published
2026 Oct 1
Container
Pharmaceutics
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/pharmaceutics18101250,
  title = {Bench-to-Bedside Development of IMNN-001: A Non-Viral IL-12 Gene Therapy for Advanced Ovarian Cancer.},
  author = {Anwer K and Sood S and Sparks J and Faller DV and Limon A and Lindborg SR},
  year = {2026},
  journal = {Pharmaceutics},
  doi = {10.3390/pharmaceutics18101250},
  url = {https://doi.org/10.3390/pharmaceutics18101250}
}

RIS

TY  - JOUR
TI  - Bench-to-Bedside Development of IMNN-001: A Non-Viral IL-12 Gene Therapy for Advanced Ovarian Cancer.
AU  - Anwer K
AU  - Sood S
AU  - Sparks J
AU  - Faller DV
AU  - Limon A
AU  - Lindborg SR
PY  - 2026
JO  - Pharmaceutics
DO  - 10.3390/pharmaceutics18101250
UR  - https://doi.org/10.3390/pharmaceutics18101250
ER  - 

APA

K, A., S, S., J, S., DV, F., A, L., & SR, L. (2026). Bench-to-Bedside Development of IMNN-001: A Non-Viral IL-12 Gene Therapy for Advanced Ovarian Cancer.. Pharmaceutics. https://doi.org/10.3390/pharmaceutics18101250

Source records